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Objective: Almonds reduce cardiovascular disease risk via cholesterol reduction, anti-inflammation, glucoregulation,
and antioxidation. The objective of this randomized, controlled, cross-over trial was to determine whether the
addition of 85 g almonds daily to a National Cholesterol Education Program (NCEP) Step 1 diet (ALM) for 6 weeks
would improve vascular function and inflammation in patients with coronary artery disease (CAD).
Research design and methods: A randomized, controlled, crossover trial was conducted in Boston, MA to test
whether as compared to a control NCEP Step 1 diet absent nuts (CON), incorporation of almonds (85 g/day) into
the CON diet (ALM) would improve vascular function and inflammation. The study duration was 22 weeks including
a 6-weeks run-in period, two 6-weeks intervention phases, and a 4-weeks washout period between the intervention
phases. A total of 45 CAD patients (27 F/18 M, 45–77 y, BMI = 20-41 kg/m2) completed the study. Drug therapies
used by patients were stable throughout the duration of the trial.
Results: The addition of almonds to the CON diet increased plasma α-tocopherol status by a mean of 5.8 %, reflecting
patient compliance (P ≤0.05). However, the ALM diet did not alter vascular function assessed by measures of
flow-mediated dilation, peripheral arterial tonometry, and pulse wave velocity. Further, the ALM diet did not
significantly modify the serum lipid profile, blood pressure, C-reactive protein, tumor necrosis factor-α or E-selectin.
The ALM diet tended to decrease vascular cell adhesion molecule-1 by 5.3 % (P = 0.064) and increase urinary nitric
oxide by 17.5 % (P = 0.112). The ALM intervention improved the overall quality of the diet by increasing calcium,
magnesium, choline, and fiber intakes above the Estimated Average Requirement (EAR) or Recommended Dietary
Allowance (RDA).
Conclusions: Thus, the addition of almonds to a NECP Step 1 diet did not significantly impact vascular function,
lipid profile or systematic inflammation in CAD patients receiving good medical care and polypharmacy therapies
but did improve diet quality without any untoward effect.
Trial registration: The trial was registered with the ClinicalTrials.Gov with the identifier: NCT00782015.
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Coronary artery disease (CAD) is one of the most common
causes of death in middle- and high-income countries [1].
Patients with CAD typically receive several medications as
part of their treatment to protect against recurrent cardiac
events and all-cause mortality. Lifestyle modifications com-
prised of regular participation in physical activity, diets low
in fat and rich in plant foods and smoking cessation are
recommended to complement polypharmacy regimens in
the management of CAD patients [2].
Patients with CAD commonly have higher circulating
cholesterol levels than their clinically healthy counterparts
[3, 4]. Thus, patients with CAD are almost always treated
with a hypocholesterolemic drug, usually a statin, and pro-
vided with recommendations for lifestyle modification for
secondary prevention. Different dietary patterns, including
the Mediterranean, DASH, and Portfolio Eating Plan diets,
can complement statin therapy as well as provide other
cardioprotective benefits [5, 6]. The American Heart As-
sociation recommends a diet rich in nuts, fruits and vege-
tables, and low in saturated fats for both primary andFig. 1 CONSORT flow diagramsecondary prevention of CAD [7]. The Lyon Diet Heart
Study was the first clinical trial to demonstrate that the
Mediterranean diet is protective in the secondary preven-
tion of CAD [8].
Among the variety of plant foods that may promote heart
health, tree nuts are high in fiber, unsaturated fat, selected
vitamins and minerals, and phytochemicals. This nutrient
profile contributes to the observed reduction in risk of car-
diovascular disease (CVD) among those who frequently
consume nuts [9, 10]. Recently, the PREDIMED trial found
that a Mediterranean diet supplemented with 30 g/day tree
nuts (almonds, hazelnuts, and walnuts) decreased risk of
cardiovascular events by 28 % [11]. Among tree nuts, al-
monds are rich in monounsaturated fat, fiber, α-tocopherol,
copper and magnesium, and phytochemicals including phy-
tosterols and polyphenols. Research on almonds suggests
they may have beneficial actions on serum cholesterol, body
weight, glucose homeostasis, inflammation, and oxidative
stress [12, 13].
In addition to their macronutrient profile, almonds pro-
vide a good source of nutrients known to modulate
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acid, and vitamin E. In a clinical trial of 60 healthy men
with risk factors for CVD, Choudhury et al. [14] tested
50 g almonds/day for 4 weeks and found improved flow-
mediated dilatation (FMD). However, no studies are avail-
able that examine the effect of almonds on endothelial re-
activity in patients with compromised vascular function.
Therefore, we hypothesized that addition of 85 g/day al-
monds to a National Cholesterol Education Program
(NCEP) Step 1 diet would improve vascular function in
patients with CAD via an increase in nitric oxide (NO)
availability and reduction in dyslipidemia, systemic inflam-
mation, and/or oxidative stress.
Methods and materials
Subjects
Patients with angiographically proven CAD were recruited
from the cardiology practice at the Boston Medical Center
in Boston, MA Fig. 1 Consecutive patients with CAD
coming to the cardiology practice were assessed for eligi-
bility. CAD was confirmed with obstructive lesion(s) on
angiogram, history of myocardial infarction, and/or posi-
tive stress test. The medical record was also reviewed
through the Boston Medical Center electronic medical
health record. Other inclusion criteria used to screen eligi-
bility also included: age, 21–80 y; body mass index (BMI),
20–41 kg/m2; body weight, <115 kg; willingness and abil-
ity to provide written informed consent; and the ability to
understand, participate, and comply with study require-
ments. The exclusion criteria included: women who are
pregnant or planning to become pregnant; clinical history
of other major illness including end-stage cancer, renal
failure, hepatic failure or other conditions that in the opin-
ion of the study physician make a clinical study inappro-
priate; treatment with an investigational new drug within
the last 30 day; history of a psychological illness or condi-
tion; taking dietary supplements (including multivitamins
and herbal supplements); and eating any nuts within 1
month of enrollment. Subjects were asked to withhold
all vasoactive medications (nitrates, calcium channel
blockers, beta blockers, angiotensin converting enzyme in-
hibitors, and other vasodilators) for 24 h prior to each
ultrasound measurement. In our previous study [15], we
reported that patients with stable CAD were able to with-
hold vasoactive medications for 24 h prior to the ultra-
sound tests without observed adverse effects. Further, a
physician was available to determine eligibility and in case
of emergencies. The study design was approved by the In-
stitutional Review Boards of Tufts University Health Sci-
ences Campus, Tufts Medical Center, and Boston Medical
Center. All participants signed a written informed consent
agreement before participating. The study was registered
in the ClinicalTrials.gov, and the registration number is
“NCT00782015”.Study design
A randomized, controlled, crossover trial was conducted to
test the hypothesis that as compared to a control NCEP
Step 1 diet absent nuts (CON), the incorporation of al-
monds (85 g/day) into the CON diet (ALM) would improve
endothelial function, diminish inflammation, and/or oxida-
tive stress. The dose of almonds was selected because
Jenkins et al. [16] illustrated a dose- dependent effect on
risk factors of cardiovascular disease and the amount of al-
monds would have a marked impact on nutrition quality of
subjects. After eligible subjects were enrolled, they were
randomized to one of the study sequences (ALM-CON or
CON-ALM) using randomly permuted blocks of size 6
(total 10 blocks). The program in the randomization.com
was employed for the randomization. After a 6 weeks run-
in period, the patients began to consume one of the diets
for 6 weeks and then the alternate diet for the other 6
weeks period with a 4-weeks washout period before the
switch. During the run-in and washout periods, all subjects
were asked to consume the CON diet. Prior to the start of
the trial, all participants were counseled about the CON
diet by a registered dietitian and on issues concerning in-
clusion of almonds to the CON diet. They were instructed
to consume almonds as snack in the morning and after-
noon. They were also instructed to replace almonds with
other food items to maintain constant energy intake during
the trial. Nutrient intakes during the trial were assessed
with 3 food recall questionnaires conducted at the study
entry (before the run-in) and the end of each intervention
phase. Participants were contacted via frequent phone calls
to encourage compliance to the study diets. Further, pack-
age bags were collected to confirm compliance at the end
of the almond intervention phase. Raw whole almonds
were generously pre-packaged at ~28.4 g servings and pro-
vided by the Almond Board of California.
Vascular reactivity
During the study, subjects visited the study site (Vascular
Research Unit, Boston Medical Center) for 4 times after
an overnight fast for assessment of vascular reactivity.
After their arrival in the morning, vital signs, including
blood pressure and body weight, were measured, followed
by urine and blood collections. Vascular reactivity was
assessed based on flow-mediated dilation (FMD), periph-
eral arterial tonometry (PAT), and pulse wave velocity
(PWV). After blood and urine collections, subjects rested
quietly in a recumbent position for 10 min. Subsequently,
arterial blood pressure was determined using an auto-
mated physiologic recorder (Dinamap, GE Health Care,
Piscataway, NJ), followed by assessment of FMD in bra-
chial artery and fingertip vessels as described previously
[17]. Brachial artery ultrasound was used to determine
FMD and hyperemic flow measured in the brachial artery.
Briefly, a 2-dimensional and Doppler ultrasound image
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hyperemia by 5-min cuff occlusion in the upper arm. Sim-
ultaneously, endothelial function in the fingertip vessels
was measured by using a digital pulse amplitude tonometry
(Endo-PAT, Itamar Medical Ltd, Caesarea, Israel) to evalu-
ate flow-mediated increases in pulse amplitude. Endo-PAT
results are expressed as the natural logarithm of the ratio of
the pulse amplitude recorded 90–120 s after cuff release to
the baseline amplitude divided by the hyperemic to baseline
ratio in the contralateral control finger (lnPAT ratio). A
higher lnPAT ratio reflects better endothelial function.
Ultrasound images of the brachial artery (Powervision
6000, Toshiba Medical, Inc., Tustin, CA) were digitized on-
line using customized hardware (Cardiovascular Engineer-
ing, Inc., Holliston, MA) and then analyzed using the
Brachial Analyzer (Medical Imaging Applications, Iowa
City, IA). The stiffness of the central aorta and conduit
arteries was also assessed in the upper extremity by meas-
uring carotid-femoral and carotid-radial pulse wave vel-
ocity, respectively, using an applanation tonometry device
(Complior SP, Artech Medical, Pantin, France) which calcu-
lated pulse wave velocity (m/s) [17]. To assess treatment ef-
fects on the endothelium-independent vasodilation of the
brachial artery, nitroglycerin (0.4 mg sublingual)-mediated
vasodilation of the brachial artery was assessed as previ-
ously described [18, 19]. The nitroglycerin portion of the
study was omitted if systolic blood pressure was
<100 mmHg, if the subject had a history of migraine
headaches, or if he/she reported a previous history of
prior adverse reaction to nitroglycerin. Thus, the sample
size was smaller for nitroglycerin mediated dilation.
Subjects were asked to take their last dose of medication
24 h before each visit, and if applicable, to avoid smok-
ing on the morning of the study.
Biochemical biomarkers
Whole blood samples were separated by centrifugation
(1,000 × g, 15 min), and plasma and serum were stored
at −80 °C until use. Plasma concentrations of total choles-
terol (TC), high-density lipoprotein-cholesterol (HDL-C),
and triglycerides (TG) were determined with a clinical
chemistry analyzer (Olympus AU400, Center Valley, PA)
according to the manufacturer’s instructions. The intra-
and inter-day coefficients of variation (CV) for TC were
1.6 and 2.8 %, for HDL-C was 3.0 and 7.0 %, and for TG
was 2.0 and 3.4 %, respectively. Inflammatory status was
evaluated by plasma concentrations of interleukin (IL)-6
and tumor necrosis factor (TNF) α, which were assessed
with a high sensitivity Quantikine quantitative sandwich
enzyme immunoassay (R&D Systems, Minneapolis, MN)
with intra- and inter-day CV of 6.9 and 6.5 % and of 5.3
and 10.8 %, respectively. High sensitivity C-reactive pro-
tein (CRP) was determined by a chemiluminescent immu-
nometric assay (IMMULITE 1000, Siemens HealthcareDiagnostics, Los Angeles, CA) with intra- and inter-day
CV of 4.2 and 4.8 %, respectively. Plasma and urinary ni-
tric oxide (NO) were determined using a commercial
assay kit [Nitrate/Nitrite Colorimetric Assay Kit Lactate
Dehydrogenase (LDH) Method, Assay Designs, Ann
Arbor, MI]. The intra- and inter-day CV for plasma was 7
and 7.6 % and for urine 5.3 and 4.7 %, respectively. Vascu-
lar cell adhesion molecule-1 (VCAM-1) and E-selectin
concentrations in plasma were determined by an enzyme-
linked immunosorbent assay (ELISA) kit (R&D Systems
and eBioscience, San Diego, CA, respectively). The intra-
and inter-day CV was 4.4 and 2.3 % for VCAM-1 and 8.8
and 10.6 % for E-selectin, respectively. Circulating oxi-
dized LDL in plasma was determined by an ELISA kit
(ALPCO, Salem, NH) with intra- and inter-day CV of 7.2
and 10.6 %, respectively. A reverse-phase gradient high
performance liquid chromatography (HPLC) method was
used for the simultaneous determination of plasma α- and
γ-tocopherol [20]. The intra- and inter-day CV were 3.8
and 6.4 % for α-tocopherol and 3.1 and 6.1 % for γ-
tocopherol, respectively. ApoA-I, ApoB, direct LDL-C,
and small dense LDL-C were measured employing an
Olympus AU400 auomated analyzer using kits (Kamiya
Biomedical Company, Seattle, WA; Beckman Coulter,
Inc., Brea, CA; and Randox Laboratories, Ltd. Crumin,
UK, respectively).
Dietary assessment
Dietary intake was estimated using a self-administered
semi-quantitative food frequency questionnaire (FFQ)
which was validated by Willett and Hu [21] before the run-
in and at the end of each treatment period. The FFQ in-
cluded 161 food items with a standard portion included as
part of the question and food-specific frequencies. In
addition, the questionnaire included questions on dietary
supplement intake, types of fats and cooking methods and
an open-ended question to include regularly consumed
foods not captured in the food list. The FFQ was analyzed
by the Harvard School of Public Health and daily nutrient
intakes were provided. Almonds consumed during the
intervention phase were not recorded in the questionnaire.
Statistical analysis
Results are expressed as mean ± standard deviation (SD). A
repeated measures analysis was performed to analyze sig-
nificance between treatments using a general linear model
with PROC GLM with treatment (ALM vs. CON), se-
quence (ALM-CON vs. CON-ALM), period (1 vs. 2), and
subjects as variables, followed by using LSMEANS to evalu-
ate the significance in differences between the ALM and
CON diets. The difference in nutrient intakes between
before the run-in and at the end of each intervention
phase was assessed using the Student’s t-test. Signifi-
cance was considered at P ≤0.05. All statistical analyses
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Inc., Cary, NC).
The sample size of this crossover study was obtained
on the basis of prior data from our laboratory with a
power of 88 % (α = 0.05) to detect a 1 % change in the
pre-specified primary endpoint of brachial artery FMD
(e.g., from 6.0 to 7.0 %) [15].
Results
Subjects
Forty five subjects completed the trial (demographic infor-
mation presented in Table 1). The mean systolic blood
pressure was 3.2 mmHg lower than the definition of stage
1 hypertension and the mean diastolic blood pressure was
within the normal range. Mean TC, LDL-C, HDL-C, and
TG values were all in the normal range. All subjects were
treated with multiple medications during the trial. The
average number of medications used before and after the
ALM diet and before and after the CON diet were 7.9 ±
3.3 (range: 3–20), 8.1 ± 3.8 (3–24), 8.2 ± 3.7 (3–24), and
8.1 ± 3.8 (3–26), respectively. The number and type of
medications were stable during the study and not signifi-
cantly different between the treatment periods. The clas-
ses of drugs used by the subjects (as percent of the 45
subjects) were: aspirin (100), statins (96), vasodilators (87),
beta-blockers (84), hypogycemics (82), platelet inhibitors
(44), angiotensin converting enzyme inhibitors (38), di-
uretics (33), proton pump inhibitors (24), and calcium
channel blockers (22). The dose of the medications was
not monitored.
Nutrient intake and status
The incorporation of almonds into the CON diet increased
the intake of vitamin E by 103 % compared to CON diet.
The ALM diet also increased plasma α-tocopherol concen-
tration by 5.8 % and decreased γ-tocopherol by 15.4 %
compared to the baseline value of the almond phase,Table 1 Characteristics of study participants at screening*
Attribute Value
Sex, F/M 27/18
Age, year 61.8 ± 8.6
Body weight, kg 86.6 ± 14.6
Body mass index, kg/m2 30.2 ± 5.1
Waist, cm (in) 102.8 ± 13.3 (40.5 ± 5.2)
Total cholesterol, mg/dL 153.4 ± 37.0
HDL-cholesterol, mg/dL 43.9 ± 11.1
LDL-cholesterol, mg/dL 82.6 ± 28.2
Total triglycerides, mg/dL 132.7 ± 82.3
Systolic Pressure, mmHg 136.8 ± 21.4
Diastolic Pressure, mmHg 74.5 ± 10.7
*Only completers are includedwhereas CON diet did not have a significant impact on ei-
ther nutrient (Table 2). Compared to the CON diet, the
ALM diet increased the post-intervention value of plasma
α-tocopherol by 10.2 % (P = 0.0065) and decreased γ-
tocopherol by 16.5 % (P = 0.047).
The addition of almonds to the CON diet increased
energy intake by 30 %, mainly due to a 163 % increase in
the intake of monounsaturated fatty acids (MUFA). The
amount of carbohydrate intake did not differ between
CON and ALM diets, but the percentage contribution of
carbohydrates to total energy intake when consuming
the ALM diet was 23 % lower than when consuming
CON diet. The amount of protein consumption during
the ALM phase was 29 % greater than that of the CON
phase but the contribution of protein to total energy in-
take was not different. Fiber intake was increased by
53 % by ALM diet as compared to CON diet. The ALM
diet led to 24, 19, and 135 % greater intake of riboflavin,
choline, and proanthocyanins, respectively, than the
CON diet. The ALM diet was also associated with a
greater intake of calcium, copper, potassium, magne-
sium, manganese, phosphate, and zinc by 25, 47, 21, 70,
40, 34, and 17 % compared to CON diet, respectively.
Almonds are rich in arginine and daily consumption of
85 g of the nuts increased the intake of this amino acid
by 62 %. The intake of other amino acids (except lysine)
was also increased by the ALM diet, ranging from 17 %
in tyrosine to 240 % in methionine.
Vascular reactivity
The main study objective was to determine whether 6
weeks of almond consumption would impact vascular
reactivity. As shown in Table 3, we did not observe a sig-
nificant effect of almonds incorporated to the NCEP step
1 diet or the NCEP step 1 diet alone on FMD, the prin-
cipal pre-specified primary endpoint, or on blood pres-
sure, nitroglycerin-mediated dilation, hyperemic blood
flow, change in forearm blood flow, arterial stiffness,
PWV, and lnPAT ratio.
Biochemical biomarkers
The lipid profiles of the subjects, including TC, HDL-C,
LDL-C, TG, and small density LDL-C, was unchanged dur-
ing the study (Table 4). VLDL-C values were calculated
from TG concentration, so changes in VLDL-C were iden-
tical to those in observed in TG. The building block of LDL
and HDL, apoprotein-B100 and -AI, respectively, was not
altered by either diet. Biomarkers of inflammation, includ-
ing plasma CRP, IL-6, and TNFα, were also not affected by
either diet. Endothelial function was evaluated plasma E-
selectin, VCAM-1, and NO. E-selectin and NO levels were
not affected by either diet. As compared to the CON diet,
the ALM diet tended to decrease sVCAM-1 by 6.1 %
(ALM vs. CON: 787 vs. 835 ng/mL, P = 0.064). Urinary NO
Table 2 The change in nutrient consumption before the run-in and at the end of the 2 interventionsa
Before run-in Almond diet Control diet
Calories, Kcal 1732.9 ± 859.1 2049.8 ± 733.0bd 1579.6 ± 784.8c
Proteins, g 70.5 ± 32.3 86.6 ± 33.1bd 67.1 ± 28.4c
Animal protein, g 44.3 ± 21.7 45.4 ± 24.8 43.9 ± 19.4
Protein, % Kcal 16.8 ± 3.6 16.9 ± 2.6 17.6 ± 3.3
Carbohydrates, g 232.0 ± 28.7 215.4 ± 101.1 215.3 ± 122.8
Carbohydrate, % Kcal 53.4 ± 7.3 40.7 ± 7.8bd 53.2 ± 8.3c
Total Fats, g 59.9 ± 37.3 98.1 ± 30.8b 50.6 ± 27.9c
Fat % Kcal 30.5 ± 6.0 44.4 ± 7.2bd 29.1 ± 6.8c
SFA, g 19.7 ± 13.2 20.3 ± 10.1b 16.4 ± 9.4cd
SFA % Kcal 9.9 ± 2.8 8.8 ± 2.2d 9.4 ± 2.8
MUFA, g 21.6 ± 13.3 48.1 ± 12.0bd 18.3 ± 10.3cd
MUFA % Kcal 11.2 ± 2.5 22.4 ± 4.9bd 10.6 ± 3.0c
PUFA, g 12.9 ± 8.3 22.5 ± 7.0bd 11.0 ± 6.7c
PUFA % Kcal 6.6 ± 1.7 10.2 ± 1.6bd 6.3 ± 1.5c
Cholesterols, mg 201.8 ± 148.6 197.8 ± 133.3 188.2 ± 94.3
Fiber, g 19.7 ± 11.2 28.7 ± 10.0bd 18.7 ± 12.5c
Glucose, g 22.3 ± 15.3 18.5 ± 11.8 19.6 ± 13.9
Sucrose, g 42.6 ± 29.0 37.1 ± 24.4 39.1 ± 31.2
Fructose, g 23.6 ± 17.4 19.9 ± 13.5 21.5 ± 16.8
Alcohol, g 2.3 ± 3.7 3.1 ± 4.3 3.3 ± 4.9
Caffeine, mg 152.7 152.5 128.2 ± 117.0 133.7 ± 139.8
Vitamins
Vitamin A, IU 10759.2 ± 6077.7 10612.5 ± 7059.1 10880.6 ± 7530.9
Vitamin C, mg 163.6 ± 183.5 117.7 ± 105.1 129.9 ± 108.3
Vitamin D, IU 405.9 ± 339.6 381.2 ± 372.2 397.3 ± 372.9
a-Tocopherol, mg 7.0 ± 3.7 34.5 ± 9.8bd 17.0 ± 29.4cd
Vitamin K, μg 143.1 ± 102.7 135.9 ± 85.5 150.2 ± 125.0
Vitamin B1, mg 3.3 ± 7.7 3.2 ± 7.7 3.1 ± 7.6
Vitamin B2, mg 4.0 ± 7.8 4.6 ± 7.8b 3.7 ± 7.7c
Niacin, mg 37.1 ± 40.2 37.1 ± 38.9 34.9 ± 38.9
Vitamin B6, mg 4.6 ± 8.6 5.7 ± 11.4 6.7 ± 17.1
Folate, μg 943.9 ± 568.3 567.4 ± 346.7d 580.1 ± 378.3d
Vitamin B12, μg 46.3 ± 127.8 57.8 ± 145.2 67.1 ± 161.2
Choline, mg 288.5 ± 140.4 325.7 ± 142.6b 274.2 ± 116.6c
Pantothenic acid, mg 10.6 ± 10.3 9.6 ± 10.3 9.7 ± 10.2
Retinol, IU 2767.5 ± 1785.9 2388.0 ± 2813.2 2412.3 ± 1965.0
Phytochemicals
Flavonoids, mg 252.2 ± 317.0 205.4 ± 252.7 204.7 ± 243.0
Proanthocyanins, mg 127.5 ± 90.9 275.2 ± 87.5bd 117.3 ± 114.8c
Carotenoids, mg 7991.7 ± 5219.5 8222.5 ± 5679.8 8459.3 ± 6667.4
Minerals
Calcium, mg 982.1 ± 651.3 1078.5 ± 594.5b 865.5 ± 490.0c
Copper, mg 2.0 ± 1.3 2.8 ± 1.8bd 1.9 ± 1.5c
Iodine, μg 37.1 ± 63.5 37.1 ± 63.5 40.5 ± 72.8
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Table 2 The change in nutrient consumption before the run-in and at the end of the 2 interventionsa (Continued)
Iron, mg 17.0 ± 11.3 19.0 ± 11.9 19.0 ± 16.0
Potassium, mg 2861.9 ± 1334.9 3261.2 ± 1329.2b 2697.2 ± 1312.5c
Magnesium, mg 345.2 ± 190.5 544.5 ± 167.9bd 319.9 ± 174.8c
Manganese, mg 4.1 ± 2.4 5.6 ± 2.4bd 4.0 ± 2.5c
Phosphate, mg 1234.0 ± 571.2 1537.5 ± 553.7bd 1144.2 ± 522.7c
Selenium, μg 5.0 ± 8.5 12.2 ± 22.4 10.3 ± 25.4
Zinc, mg 14.4 ± 8.9 16.9 ± 9.6bd 14.5 ± 11.2c
Amino acids
Alanine, g 3.3 ± 1.6 4.2 ± 1.6bd 3.2 ± 1.3c
Arginine, g 3.9 ± 1.9 6.0 ± 1.8bd 3.7 ± 1.5b
Aspartic acid, g 6.5 ± 3.0 8.6 ± 3.0bd 6.1 ± 2.6c
Cysteine, g 1.1 ± 0.5 1.2 ± 0.5b 1.0 ± 0.5c
Glutamic acid, g 13.7 ± 6.3 18.3 ± 6.3bd 12.9 ± 5.7c
Glycine, g 3.0 ± 1.4 4.2 ± 1.4bd 2.8 ± 1.2c
Histidine, g 1.9 ± 0.9 2.4 ± 0.9bc 1.8 ± 0.8c
Isoleucine, g 3.2 ± 1.5 3.7 ± 1.5b 3.0 ± 1.3c
Leucine, g 5.6 ± 2.6 6.7 ± 2.7b 5.3 ± 2.2c
Lysine, g 4.7 ± 2.2 5.2 ± 2.4 4.6 ± 1.9
Methionine, g 1.6 ± 0.7 1.7 ± 0.8b 1.5 ± 0.6c
Phenylalanine, g 3.2 ± 1.4 4.0 ± 1.5bd 3.0 ± 1.3c
Proline, g 4.6 ± 2.2 5.0 ± 2.2b 4.2 ± 2.0c
Serine, g 3.3 ± 1.5 3.9 ± 1.5b 3.1 ± 1.3c
Threonine, g 2.6 ± 1.2 3.1 ± 1.2b 2.5 ± 1.0
Tryptophan, g 0.8 ± 0.3 0.9 ± 0.3b 0.7 ± 0.3c
Tyrosine, g 2.4 ± 1.1 2.7 ± 1.2b 2.3 ± 1.0c
Valine, g 3.7 ± 1.7 4.3 ± 1.7b 3.5 ± 1.5c
aAbbreviation: CHO carbohydrates, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids
bcMeans with different letters between almond and control diets differ, tested by LSMEANS
dMeans differ from those of before the run-in, tested by Student’s t-test
Table 3 The effect of almonds on measures of vascular activitya
Biomarker Almond diet Control diet
Pre Post Pre Post
SBP, mmHg 135 ± 21 135 ± 20 136 ± 26 135 ± 23
DBP, mmHg 73.3 ± 10.3 73.8 ± 9.5 74.1 ± 10.7 73.7 ± 10.6
FMD, % 7.7 ± 3.3 8.3 ± 3.8 7.8 ± 3.5 7.5 ± 3.7
NMD, %b 12.0 ± 5.4 11.3 ± 5.3 11.2 ± 5.4 10.4 ± 5.2
Carotid-femoral PWV, m/s 8.6 ± 1.6 8.4 ± 1.8 8.4 ± 1.7 8.4 ± 1.3
Carotid-radial PWV, m/s 8.7 ± 1.6 8.5 ± 1.6 8.7 ± 1.8 8.2 ± 1.4
Hyperemic blood flow, mL/min 984 ± 304 968 ± 334 1095 ± 477 964 ± 339
Post velocity, cm/s 114 ± 28 109 ± 27 131 ± 99 107 ± 28
Change in FBF (%) 657 ± 301 582 ± 221 592 ± 210 603 ± 227
LnPAT 0.61 ± 0.39 0.43 ± 0.47 0.47 ± 0.46 0.50 ± 0.40
aAbbrevations: DBP diastolic blood pressure, FBF forearm blood flow, FMD flow mediated dilation, LnPAT natural log of the pulse amplitude tonometry measured in
the finger, PWV pulse wave velocity, SBP systolic blood pressure
bNitroglycerin-mediated dilation (NMD) of the brachial artery, n = 22 participants because some subjects did not participate in this portion of the study if their SBP
was <100 mmHg, if they had a history of migraine headaches or if they reported a previous history of prior adverse reaction to nitroglycerin
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Table 4 Effect of almonds on biochemical biomarkersa
Biomarker Almond diet Control diet
Pre Post Pre Post
Plasma Lipid Profile
Total cholesterol, mg/dL 146.2 ± 37.8 146.9 ± 32.4 149.8 ± 43.2 148.6 ± 38.3
HDL-C, mg/dL 41.0 ± 11.2 41.7 ± 11.2 41.7 ± 10.8 43.3 ± 15.6
LDL-C, mg/dL 78.7 ± 28.6 80.3 ± 26.2 82.67 ± 36.3 77.9 ± 26.3
Total triglycerides, mg/dL 123.6 ± 90.9 124.3 ± 60.7 129.2 ± 75.5 131.4 ± 60.2
Small dense LDL-C, mg/dL 30.9 ± 14.1 32.8 ± 14.1 33.7 ± 19.9 29.6 ± 12.1
Apo-B100, mg/dL 69.0 ± 20.8 71.9 ± 19.0 72.3 ± 25.0 67.1 ± 19.8
Apo-AI, mg/dL 118.0 ± 22.0 118.4 ± 22.1 118.8 ± 21.0 121.0 ± 28.1
Plasma Inflammatory cytokines
C-reactive Protein, mg/L 4.0 ± 6.4 3.3 ± 4.2 4.5 ± 5.7 3.9 ± 5.1
TNFα, pg/mL 1.8 ± 1.8 1.8 ± 1.6 1.6 ± 1.4 1.7 ± 1.5
IL-6, pg/mL 3.5 ± 2.2 3.6 ± 2.5 3.8 ± 2.9 4.1 ± 2.9
Endothelial function
Plasma E-selectin, ng/mL 28.7 ± 19.6 28.7 ± 18.6 29.4 ± 20.7 27.5 ± 17.7
Plasma VCAM-1, ng/mL 854 ± 377 787 ± 363b 826 ± 380 835 ± 341
Plasma nitric oxide, μmol/L 38.2 ± 12.6 41.8 ± 15.8 42.1 ± 17.4 39.3 ± 13.1
Urinary nitric oxide, μmol/mg creatinine 0.62 ± 0.59 0.56 ± 0.36c 0.63 ± 0.33 0.47 ± 0.29
Oxidative stress
Circulating oxidized LDL, mU/mL 741 ± 704 727 ± 637 729 ± 604 778 ± 746
α-Tocopherol, μg/dL 1080 ± 453 1143 ± 388** 1120 ± 362 1037 ± 347
γ-Tocopherol, μg/dL 156 ± 82 132 ± 69* 175 ± 104 158 ± 84
aAbbreviation: VCAM-1 vascular cell adhesion molecule-1
bP = 0.0641, cP = 0.09, *P <0.05, **P <0.01, statistical significance between post values tested by LSMEANS
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of the post-CON diet (0.56 vs. 0.47 μmol/mg creatinine,
P = 0.09).
Discussion
This randomized, crossover clinical trial was designed to
examine the impact of almonds incorporated to a NCEP
step 1 diet on vascular reactivity and other CVD risk fac-
tors in patients with CAD, using the NCEP step 1 diet
without nuts as the control phase. Neither the ALM nor
CON diet affected measures of endothelial vasodilator
function, including FMD, lnPAT ratio, and PWV, a meas-
ure of arterial stiffness. In addition, no significant effect of
ALM compared to CON on the plasma lipid profile or se-
lected biomarkers of inflammation, endothelial function,
and oxidative stress was observed.
Endothelial dysfunction, a critical early event in the
pathogenesis of atherosclerosis characterized by the re-
duced bioavailability of NO (a vasodilator) and the in-
creased expression of cellular adhesion molecules, is related
to perfusion abnormalities and subsequent ischemic events
[22]. However, we found no beneficial effect of chronic al-
mond consumption on vascular reactivity reflected by
FMD, NMD, lnPAT ratio, and PWV, even though the ALMdiet significantly increased intake of several nutrients asso-
ciated with improved endothelial function in other studies.
Our results are consistent with the study by López-Uriarte
et al. [23] in which a 12-weeks intervention study with
mixed nuts (15 g walnuts, 7.5 g almonds, and 7.5 g hazel-
nuts) did not show an effect on endothelial function
assessed by PAT in patients with Metabolic Syndrome. In
contrast, Choudhury et al. [14] reported that 50 g almonds/
day for 4 weeks improved FMD asymptomatic men as
compared to no almonds (3.6 vs. 2.9 %). Similarly, a 4-
weeks intervention where hazelnuts replaced ~20 % daily
energy intake significantly improved FMD (56.6 %) from
15.2 to 21.8 % as compared to control in 21 adults with
hypercholesterolemia [24]. Further, Katz et al. [25] found
the intake of 56 g/day walnuts for 8 weeks significantly in-
creased FMD from 8.8 to 10.2 % in overweight patients
with Metabolic Syndrome, accompanied by a reduction in
systolic blood pressure. Ros et al. [26] also reported that
walnuts incorporated into a cholesterol-lowering Mediter-
ranean diet to replace 32 % MUFA energy improved
endothelium-dependent FMD from 4.1 to 5.1 % in subjects
with hypercholesterolemia. Differences in the study design,
subject characteristics (including health status, lifestyle, and
drug therapy), and nut nutrient composition may account
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our patients were receiving multiple risk-reduction therap-
ies and had well-controlled lipid profiles at baseline. The
discrepant results might also reflect differences in the nutri-
ent content of the various tree nuts; e.g., walnuts contain
more polyunsaturated fats, including α-linoleic acid, than
MUFA compared to other tree nuts. However, the exact
mechanism(s) for the discrepancy between our studies and
others remain to be explored in the future studies.
The effect of chronic consumption of almonds and
other tree nuts on blood biomarkers of CVD have been
demonstrated, although the results are mixed with re-
gard to individual biomarkers. Previously, we observed
that almonds replacing 20 % daily caloric intake in a
NCEP step 2 diet improved lipid profile in Chinese pa-
tients with type 2 diabetes [27]. The benefits of almonds
on the lipid profile of healthy adults or those who have
hypercholesterolemia, dyslipidemia, and/or prediabetes
have been reported in several studies [28–33]. More re-
cently, Nishi et al. [34] found that almond consumption
at 37 or 73 g/day for 4 weeks increased oleic acid and
MUFA content in serum TG and non-esterified fatty
acid fractions. Jenkins et al. [16] extrapolated from their
dose–response study to suggest that each 7-g portion of
almonds would induce a 1 % reduction in LDL-C. In
contrast, we did not find that the addition of almonds to
the NCEP step 1 diet affected TC, TG, HDL-C, LDL-C
or small density LDL-C. However, as the lipid profile at
study baseline in our subjects were being maintained
within normal ranges by statins and/or the NCEP Step 1
diet, it seems unlikely that any single food would enable
a further significant improvement.
Inflammation plays a critical role in the risk for and pro-
gression of CVD such that inflammatory biomarkers like
CRP and IL-6 are generally recognized as independent pre-
dictors of atherosclerosis [35–37]. Cell adhesion molecules,
including VCAM-1, E-selectin, and intercellular adhesion
molecule-1 (ICAM-1), also contribute to the pathogenesis
of this condition [38]. Jiang et al. [39] noted in the Multi-
Ethnic Study of Atherosclerosis that inflammatory bio-
markers were inversely associated with an increased fre-
quency of nut and seed consumption. Consistent with this
observational data, we previously found that almonds de-
creased IL-6 and CRP, and TNF-α in Chinese patients with
type 2 diabetes but did not affect ICAM-1 or VCAM-1
[40]. Rajaram et al. [41] also reported that almond intake
diminished CRP in free-living healthy adults although no
dose–response relationship was noted. In contrast, Damas-
ceno et al. [28] reported that neither almonds nor walnuts
affected CRP, ICAM-1 or VCAM-1 in asymptomatic adults
with moderate hypercholesterolemia. In our study of well-
controlled CAD patients, neither the ALM nor the CON
diet had an impact on IL-6, CRP, TNF-α or E-selectin.
However, there was a trend toward reduction in VCAM-1after the ALM phase. It is noteworthy that the concentra-
tion of CRP, IL-6 and TNF observed in this study appeared
to be slightly larger than the values found in Chinese pa-
tients with type 2 diabetes [27] or coronary heart disease
[42] and in the prospective Multi-Ethnic Study of Athero-
sclerosis [39]. Thus, it is plausible that the larger starting
values in inflammatory biomarkers may account for the ob-
served null results. Also, the null effect may be attributed to
the direct or indirect anti-inflammatory effects of multiple
medications taken by the patients. Similar to the slight im-
provement in VCAM-1, urinary excretion of NO tended to
increase with the ALM diet. These trends suggest a possible
modest benefit of almond intake on endothelial function in
CAD patients, so further research on this potential benefit
is warranted.
Almonds are a good source for a number of nutrients,
with 85 g providing >10 % of the daily value of many vita-
mins (vitamin E, riboflavin, niacin, thiamin, and folate),
minerals (calcium, copper, iron, magnesium, manganese,
phosphorus, potassium, zinc), and fiber as well as arginine
and oleic acid [43]. In addition, 85 g almonds contain
111 mg β-sistosterol, 9.3 mg flavonoids, and 156.5 mg
proanthocyanins [44]. Relative to the CON diet, the ALM
diet had a more positive impact on nutritional quality by in-
creasing intake of calcium, magnesium, choline, and fiber
above recommended values. The intake of these nutrients
were below either the EAR or RDA when the subjects were
consuming CON diet. These results are consistent with
Jaceldo-Siegl et al. [45] who found the addition of 52 g/day
almonds to the habitual diets of healthy men and women
for 6 months significantly increased their intakes of MUFA,
PUFA, fiber, vegetable protein, vitamin E, copper, and mag-
nesium and decreased the amount of trans fatty acids, ani-
mal protein, sodium, cholesterol, and sugars. Consumption
of dietary polyphenols is associated inversely with the risk
of CVD and cancer [46–48]. As almonds contain an array
of polyphenols, particularly proanthocyanins, they can be
part of recommended guidelines for healthy diets rich in
plant foods.
The study participants were patients with angiographic-
ally proven CAD and were taking on average 8 medications
daily. Their polypharmacy regimen remained stable and ef-
fective during the 6-weeks almond intervention, suggesting
intakes at 85 g/day are absent any indication of untoward
drug-food interactions. Importantly, the change in the pro-
file of nutrient intake during the ALM phase matched well
general dietary recommendations to reduce the risk of
CVD. It is also noteworthy that even though the ALM diet
increased the percent of total calorie intake from fat from
29.1 to 44.4 %, there was no adverse effect on the lipid pro-
file. These results are consistent with the favorable effect of
almonds on lipid profiles reported by others [49].
Our study had several limitations. The study duration
of 6 weeks for each arm is a relatively short period to
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a longer intervention or larger sample size may have re-
sulted in a statistically significant reduction in plasma
VCAM-1 and increase in urinary NO. Conversely, while
we found no untoward impact of the ALM diet on con-
current drug therapy, we cannot exclude the develop-
ment of such interactions over a longer period. It is
possible the study design, including a 6-weeks run-in
period on the NCEP Step 1 diet that was then continued
throughout both study arms and the 4-weeks washout,
may have masked an impact of the almond intervention.
Similarly, efficacy of the polypharmacy regimens of the
subjects may have largely achieved the maximal benefit
possible in these patients on the outcome parameters of
vascular reactivity, inflammation, and oxidative stress.
Finally, the study might be underpowered for both the
primary and secondary outcome measures since the
power calculation was performed based on the improve-
ment in FMD.
Conclusions
This randomized, controlled, cross-over trial revealed no
significant impact of the incorporation of 85 g/day almonds
to a NCEP Step 1 diet on FMD and other measures of vas-
cular reactivity. Compliance to the almond intervention
was good, as confirmed by an elevation of α-tocopherol sta-
tus, and was associated with an improvement of dietary
quality reflected by increased intakes of fiber, amino acids
(especially arginine), the minerals calcium and magnesium,
choline, and proanthocyanins. Positive trends were ob-
served in a reduction of circulating VCAM-1 and an in-
crease of urinary NO, though these changes did not achieve
statistical significance. The addition of almonds to the con-
trol diet improved dietary quality beyond that already
achieved by the NCEP step 1 diet, particularly by increasing
the intake of fiber, calcium, magnesium, choline, proantho-
cyanins, and arginine. The generous consumption of al-
monds was safe in CAD patients, absent any indication of
adverse interactions with their polypharmacy regimens.
Overall, our results provide further support for patients
with CVD that almonds can be part of a healthy diet.
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